These immune cell infiltrates were further accentuated following treatment with programmed cell death protein 1 (PD-1) inhibitors, suggesting that KMT2D mutations could identify pancreatic cancer patients who may benefit from ICB therapy. The gene discussed is PDCD1; the disease is familial pancreatic carcinoma.